This Is MS Multiple Sclerosis Knowledge & Support Community

... that selectively deplete B cells (rituximab, ocrelizumab and ofatumumab), agents that less specifically deplete lymphocytes (alemtuzumab and cladribine) and autologous haematopoietic stem cell transplantation, in which the immune system is unselectively ablated and reconstituted. We consider ...

... (n = 28). The patients with relapsing MS received either monthly infusions of natalizumab (n = 29) or a pulsed IRT with alemtuzumab (n = 15) or cladribine (n = 6). B-cell subpopulation frequencies were determined by flow cytometry, and transcriptome profiling was performed using Clariom D arrays. ...

... in multiple sclerosis lesions and normal appearing white matter https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-021-01306-3 Cladribine inhibits the biological activity of microglial cells https://www.sciencedirect.com/science/article/pii/S1567576922000558

Covid vaccine response was significantly lower in MS patients taking Ocrevus, fingolimod and cladribine.

Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

https://pubmed.ncbi.nlm.nih.gov/34810244/

... I’ve half-heartedly sniffed around for a neuro willing to carry on the torch and haven’t had any luck. New guy also won’t do the more affordable cladribine injections in place of the ridiculously priced mavenclad. <-I haven’t looked. Is it even worse w/recent inflation? So, I guess we will get ...

... Outcomes. The best therapeutic agent in reported efficacy amongst the three analyzed was Ofatumumab, ranked first in hierarchy, Ozanimod and Cladribine following in the second and third place, respectively. Conclusions. According to ABN’s 2015 guidelines, Cladribine was ranked between the ...

... resemble that recently described in humans receiving pulsed immune reconstitution therapy with the disease-modifying compounds, alemtuzumab and cladribine. Our study suggests that JM4 therapy may have widespread clinical applicability for long-term treatment of inflammatory demyelinating diseases ...

brought this one over from the cladribine topic

Illuminating vitamin D effects on B cells – the multiple sclerosis perspective (2016)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754614/

It is not an official but regulatory agencies considered the highly active MS (HAMS) separated from the rest in their approval processes for cladribine/mavenclad (https://www.merckgroup.com/en/news/mavenclad-25-08-2017.html) Now is the same for Russia https://nnp.ima-press.net/nnp/article/view/1359 ...

... the risk. We do recommend these patients should be explained of these risks. 4. Significant risk. Alemtuzumab, ocrelizumab, rituximab, and Cladribine may increase the risk of acquiring and severity of COVID-19. They should be carefully considered before starting in new patients and those ...

... for treatment of MS in the United States... Other chemotherapeutics that have been tested in MS to date include cyclophosphamide, methotrexate, cladribine , and the mAbs alemtuzumab and rituximab. While there has been varying evidence of efficacy for these compounds, each appears to be associated ...

... are on. a. Interferon or Glatiramer acetate/glatiramoids b. Teriflunomide, Fingolimod, Siponimod, Dimetylfumarate, Natalizumab, c. Ocrelizumab, Cladribine, Mitoxantrone, Cyclophosphamide d. Alemtuzumab, Hematopioetic Stem Cells Transplantation • None Q4) Which was/were your previous treatment(s) ...

... are on. a. Interferon or Glatiramer acetate/glatiramoids b. Teriflunomide, Fingolimod, Siponimod, Dimetylfumarate, Natalizumab, c. Ocrelizumab, Cladribine, Mitoxantrone, Cyclophosphamide d. Alemtuzumab, Hematopioetic Stem Cells Transplantation • None Q4) Which was/were your previous treatment(s) ...

... information for these drugs. Mayzent (siponimod): https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/mayzent.pdf Mavenclad (cladribine): https://www.emdserono.com/content/dam/web/corporate/non-images/country-specifics/us/pi/mavenclad-pi.pdf Mavenclad has a black box warning ...

2020 Mar 14 Department of Neurology of Lublin Medical University, Lublin, Poland Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients. https://www.ncbi.nlm.nih.gov/pubmed/32256946 ...